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AbstrAct
Targeting the ubiquitin–proteasome system (UPS) and ubiquitin-like signalling 
systems (UBL) has been considered a promising therapeutic strategy to treat cancer, 
neurodegenerative and immunological disorders. There have been multiple efforts 
recently to identify novel compounds that efficiently modulate the activities of 
different disease-specific components of the UPS-UBL. However, it is evident that 
polypharmacology (the ability to affect multiple independent protein targets) is a basic 
property of small molecules and even highly potent molecules would have a number 
of “off target” effects. Here we have explored publicly available high-throughput 
screening data covering a wide spectrum of currently accepted drug targets in order 
to understand polypharmacology of small molecules targeting different components 
of the UPS-UBL. We have demonstrated that molecules targeting a given UPS-UBL 
protein also have high odds to target a given off target spectrum. Moreover, the off 
target spectrum differs significantly between different components of UPS-UBL. This 
information can be utilized further in drug discovery efforts, to improve drug efficiency 
and to reduce the risk of potential side effects of the prospective drugs designed to 
target specific UPS-UBL components.
IntroductIon
The ubiquitin–proteasome system (UPS) is essential 
for the turnover and biological function of most proteins 
[1-3]. In short, ubiquitin is a protein with 76 amino acids, 
which is activated in an ATP-dependent manner by a 
ubiquitin-activating enzyme commonly referred to as E1. 
In the next step ubiquitin is transferred by an ubiquitin-
conjugating enzyme (commonly referred to as E2) that, 
together with an ubiquitin-protein ligase (commonly 
referred to as E3), specifically attaches ubiquitin to a target 
protein through the amino group of a lysine residue [4]. 
The targeted protein can be polyubiquitylated (the addition 
of several ubiquitins to a single lysine residue in a protein) 
or multiubiquitylated (addition of single or several 
ubiquitin(s) to several lysines in one protein). Initially, 
protein ubiquitylation was considered only in the context 
of signalling for 26S proteasome-mediated degradation 
of the targeted protein (the case of polyubiquitination) 
[5]. Our current understanding, however, is much 
wider: there are diverse, nondegradative functions of 
protein ubiquitylation including the regulation of DNA 
repair,transcription, mRNA metabolism and splicing 
[1, 6-10]. Moreover, the 26S proteasome is subject to 
ubiquitination by itself, which affects its activity [11]. 
In addition, protein ubiquitylation is regulated tightly by 
complex mechanisms and is a reversible process: ubiquitin 
molecules can be removed by deubiquitylating enzymes 
(DUBs) [12].
Recently a number of regulatory cascades very 
similar to UPS have been discovered, the ubiquitin like 
modifiers (UBL) [13, 14]. By marking proteins with 
ubiquitin-like conjugates, the cell regulates activity 
of multiple downstream proteins and, thus, controls 
many important regulatory pathways. The structure of 
enzymological reactions that are involved in protein 
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modifications by ubiquitylation is analogous to that 
used by ubiquitin-like cascades. One of the best studied 
ubiquitin-like proteins is small ubiquitin-related modifiers 
SUMO [15]. The conjugation of SUMO to target proteins 
regulates cell-cycle control, nuclear transport and the 
response to viral infections [16]. Three SUMO isoforms 
are currently known in man with functionally distinct 
roles. At present, about a dozen different ubiquitin-like 
cascades have been described with varying degrees of 
completeness [17].
Destabilization of the normal UPS function as well 
as defects in functionality of UBL signalling cascades 
have been shown to be linked to multiple pathological 
conditions such as cancer and neurodegenerative 
disorders [17, 18]. Although our understanding of the 
role of the UPS-UBL in various complex diseases is far 
from complete, there are examples of successful drug 
developments targeting the system. Bortezomib is the 
first drug targeting the UPS (inhibition of the proteasome) 
that was approved by the FDA for treatment of multiple 
myeloma in 2003 [19]. The selectivity of proteasome 
inhibition for killing tumour versus normal cells (normal 
cells also experience some toxic effects due to abnormal 
function of the proteasome) by Bortezomib was somewhat 
surprising. The commonly accepted explanation for this is 
that tumour cells (in particular white blood cells normally 
responsible for producing antibodies) have higher 
concentrations of aberrant proteins that are constantly 
degraded by the UPS making them more sensitive to the 
effects of proteasome inhibition [17, 18]. 
The success of Bortezomib along with our increasing 
understanding of the UPS-UBL and its potential role in 
human diseases has provoked significant interest in the 
development of drugs that can target specific components 
of the UPS-UBL pathways, thus modifying UPS-UBL 
function [18]. The current trend is the development of 
compounds targeting specific proteins of the UPS [20]. 
There have been multiple efforts recently to develop high-
throughput screening (HTS) assays to identify drugs that 
modulate the activity of different components of ubiquitin 
or ubiquitin-like cascades [21-23]. In the public domain, 
we were able to find more than a dozen of such HTS (see 
Table 1), with each reporting thousands of molecules to 
be efficient modulators and, therefore, each reporting 
thousands of potential drug leads to act on specific UPS 
or UBL components. 
The current process of drug discovery and 
subsequent (pre-)clinical development involves several 
stages; identification of molecules that act on a specific 
target is only the first step in this timely process. In 
the next step selected drug candidates are subjected to 
various tests to investigate potential off targets which 
would predefine their specific toxicity or side effects 
[24]. On the one hand, selection of many drug candidates 
obviously increases the chances to find the one with 
optimized safety parameters; on the other hand, testing 
many drug candidates towards a whole spectrum of 
potential off targets is virtually impossible. At this stage, 
it is imperative to introduce some rationale for selecting 
potential risk factors (such as defining the most probable 
off target effects) and, therefore, to optimize the number 
of tests needed. This rationale could be introduced by 
table 1: High-throughput screening assays publicly available in the Pubchem database modelling different 
components of ubiquitin or ubiquitin-like cascades.
Assay Id Assay title Active Molecules
screened 
Molecules
485273 uHTS identification of UBC13 Polyubiquitin Inhibitors via a TR-FRET Assay 1540 328 071
588478 A screen for small molecule inhibitors of the human deubiquitinating enzyme, UCH37 1078 329 843
602429 uHTS identification of SUMO1-mediated protein-protein interactions 1206 362 962
2716
Luminescence  Microorganism Primary HTS to Identify Inhibitors of the 
SUMOylation Pathway Using a Temperature Sensitive Growth Reversal 
Mutant Mot1-301
3324 315 446
2006 uHTS HTRF assay for identification of inhibitors of SUMOylation 1039 289 855
2540 HTS Luminescent assay for identification of inhibitors of Sentrin-specific protease 8 (SENP8) 4122 326 358
2599 uHTS Luminescent assay for identification of inhibitors of Sentrin-specific protease 6 (SENP6) 5820 324 660
434973 uHTS Luminescent assay for identification of inhibitors of Sentrin-specific protease 7 (SENP7) 4906 326 853
602440 uHTS Fluorescent Assay Using Nedd8 Protein Substrate for Identification of Inhibitors of Sentrin-Specific Protease 8 (SENP8) 2342 361 826
624204 uHTS identification of small molecule inhibitors of the catalytic domain of the SUMO protease, SENP1 in a FRET assay 774 363 394
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mining of publicly available HTS screens covering a wide 
spectrum of potential drug targets in various complex 
diseases. 
In this article we are going to review several 
recently published high-throughput screening assays 
that aimed to identify potential drug leads targeting 
different components of the UPS-UBL (see Table 1). 
Furthermore, we provide comparative analyses of these 
screens versus the large number (> 1000) of HTS target-
oriented screens publicly available in the PubChem 
repository. The possibility of such comparison arises 
from the lucky coincidence that the chemical libraries 
used in most of these screens are very similar, i.e. screens 
done independently by different labs with biologically 
independent assays (targets) share a significant number of 
the same screened molecules. This allows one to compute 
for UPS (UBL) targets the cross target correlation versus 
the spectrum of other targets available in PubChem: the 
odds of molecules to target any protein from the spectrum 
if the molecule targets the UPS (UBL). Therefore, for each 
UPS (UBL) target we obtain a list of top off targets which 
have high odds to be targeted by potential drug leads. We 
also provided analyses of discovered top potential off 
targets on the subject of drug efficiency and drug safety 
issues.
Inference of off target spectrum for uPs (ubL) 
targets
PubChem BioAssay [25] repository stores the results 
of biochemical HTS target oriented assays. Based on the 
PubChem BioAssay data model, results of HTS target 
oriented assays, in simple terms, could be interpreted as 
a subset of small molecules reported to inhibit (in rare 
cases activate) the targeted protein. The abundance of 
this information (> 1000 independent assays) from the 
PubChem BioAssay repository could be integrated on a 
large scale to derive binding spectra for approximately half 
of the million molecules across several hundred proteins. 
Many of these molecules have been tested in UPS (UBL) 
assays. Let us denote KA to be the number of active 
molecules (molecules exhibiting activity in the assay at 
relevant concentrations) in the HTS UPS (UBL) assay 
and as KB the number of inactive molecules. For each off 
target protein “Z” we count the number (kA) of the active 
molecules (from the UPS assay) which target “Z” (have 
been reported in the other HTS assay as active versus “Z”) 
and kB is the number of inactive molecules which target Z. 
Odds for the molecules (to be active) targeting “Z” is (kA/
kB) while the same odds for the molecules which do not 
target “Z” is ((KA-kA)/(KB-kB)). The odds ratio is (kA/kB) 
/ ((KA-kA)/(KB-kB)) and indicates the increase/decrease of 
odds for a molecule to target “Z” while targeting the UPS-
UBL protein. Significance of the odds ratio is computed 
using X2- distribution and the adjustment of p-values for 
multiple testing (each target one hypothesis) is done using 
the FDR procedure [26-29]. 
ubc13 Polyubiquitin Inhibitors
Ubc13 is an unusual E2 ubiquitin-conjugating 
enzyme which is only active as a heterodimer with another 
Table 2: Top off targets for molecules inhibiting UBC13 (based on data from assay “uHTS identification 
of ubc13 Polyubiquitin Inhibitors via a tr-FrEt Assay”). 
(target): activity odds ratio kA* 
KA 
(the 
number 
of Active 
molecules)
kB**
KB *** 
(the number 
of InActive 
molecules)
P-value
(MAP4K2):inhibitor:mutant 53.06 231 1538 743 223822 < 1.57E-280
(APAF1):inhibitor 41.71 406 1538 1908 223822 < 1.57E-280
(RAD52):inhibitor 36.35 140 1538 615 223822 1.24E-152
(MAP4K2):inhibitor 27.8 395 1538 2748 223822 < 1.57E-280
(RAD54L):inhibitor 20.16 55 1538 411 223822 3.08E-49
(ATXN2):inhibitor 19.95 221 1538 1867 223822 1.24E-186
(MLLT3)[AF4 peptide]:inhibitor 19.54 118 1538 948 223822 3.21E-101
[Peg3 Promoter]:inhibitor 18.08 389 1538 4114 223822 2.93E-302
(MITF):inhibitor 16.78 202 1538 1999 223822 7.99E-158
(PREPL):inhibitor 12.14 153 1538 2018 223822 4.28E-102
(PPP1CA):inhibitor 10.24 164 1538 2578 223822 1.49E-98
*     kA – the number of Active molecules known to have off target activity
**   kB – the number of InActive molecules known to have off target activity
*** Molecules that have no experimentally validated targets are not accounted in the table
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E2 enzyme and produces polyubiquitin chains exclusively 
linked at lysine residue 63 of ubiquitin. Ubc13 specifically 
ubiquitinates Tumor Necrosis Factor Receptor-Associated 
Factors (TRAFs), a family of adapter proteins. Ubc13-
mediated ubiquitination of TRAFs is recognized as a 
critical step in signalling by TNFRs during the innate and 
acquired immune responses [30]. Inhibition of Ubc13 
is considered as a potential strategy for development of 
novel immunosuppressive, anti-inflammatory agents as 
well as agents for treatment of neurodegenerative diseases 
[31]. In vitro high-throughput screening assays based on 
the principal of time-resolved fluorescence resonance 
energy transfer (TR-FRET) have been developed to 
identify potential inhibitors of Ubc13 activity [32]. 
Terbium-ubiquitin and fluorescein-ubiquitin have been 
used to generate a FRET reaction. In total, a library of 328 
071 compounds were screened and 1540 were reported as 
active (efficiently inhibiting Ubc13 at clinically relevant 
concentrations). 
The top ten potential off target activities for the 
molecules inhibiting Ubc13 are presented in Table 2. 
For example, the ability of a molecule to inhibit Ubc13 
significantly increases the odds (~ 40 fold) for the 
molecule to additionally inhibit APAF1. In total, 2314 (406 
+ 1908) molecules which were tested in the Ubc13 screen 
demonstrated the potential to inhibit APAF1 and 406 of 
them exhibited potent inhibition of Ubc13 while 1908 did 
not. Observed odds for a molecule to inhibit Ubc13 in the 
screen is ~ 0.006 (1538/ 223822), while observed odds for 
the molecules experimentally validated to inhibit APAF1 
is approximately 40 times higher ~ 0.21 (406/1908). 
Thus, we observe a strong association between Ubc13 and 
APAF1: molecules targeting one protein have a reasonable 
chance to target the other as an off target. 
Recent evidence has implicated the E3 ligase 
activity of TRAFs in the pathogenic aggregation of mutant 
proteins in neurodegenerative diseases such as Huntington 
disease [33]. Instead of conventional polyubiquitination, 
TRAF6 promotes atypical ubiquitination (with the Ubc13 
as the E2) of mutated misfolded proteins and, thereby, 
prevents them from degradation [34, 35]. Recently APAF1 
dominant negative inhibition was tested for its anti-
apoptotic effect on degenerating nigrostriatal neurons in 
a 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP) 
model of Parkinson’s disease and was shown to inhibit 
MPTP toxicity [36]. Thus, both Ubc13 and APAF1 are 
potential therapeutic targets in Parkinson’s disease but 
with different mechanism of action. Our analysis reveals 
that Ubc13 and APAF1 are frequently targeted together 
by small molecules as observed from the available HTS 
screens. This makes the Ubc13 and APAF1 pair an 
attractive multitarget for development of therapeutics with 
polypharmacological mechanisms of action in Parkinson’s 
disease.
Inhibitors of the human deubiquitinating enzyme 
(ucH37)
Deubiquitinating enzymes (DUB) represent a group 
of cysteine proteases that cleave the isopeptide bond 
between ubiquitin and its conjugated proteins [37]. The 
HTS assay (PubChem Id 588478) aims to identify small 
molecule inhibitors of human UCH37, which is tightly 
associated with the proteasome. Specifically, this screen 
sought to identify small molecules that inhibit the increase 
in fluorescence resulting from the UCH37 mediated 
cleavage of a fluorescent substrate, ubiquitin-7-amido-4-
methylcoumarin (Ub-AMC). In total, a library of 329843 
small molecules was screened and 1078 molecules were 
reported as active (efficiently inhibiting UCH37 at low 
concentration).
The top ten potential off target activities for the 
molecules inhibiting UCH37 are presented in Table 3. 
For example, the ability of a molecule to inhibit UCH37 
significantly increases the odds (~ 30 fold) for the 
molecule to inhibit TDP2 (tyrosyl-DNA phosphodiesterase 
2). In total, 965 (119 + 846) molecules tested in the assay 
have been reported in other HTS screens as efficient 
inhibitors of TDP2 and 119 of them demonstrated potent 
inhibition of UCH37 in the assay. Observed odds for a 
molecule to inhibit UCH37 in the screen is ~ 0.005 (2130/ 
238331), while observed odds for the molecules known 
to inhibit TDP2 is approximately 30 times higher ~ 0.14 
(119/846). Thus, we observe strong association between 
UCH37 and TDP2: molecules targeting one protein have 
a reasonable chance to target the other as an off target. 
Human USPs are considered as novel targets 
for therapeutic intervention in a number of human 
cancers, including prostate, colon and breast cancer as 
well as acute lymphoblastic leukemia [38]. Tyrosyl-
DNA phosphodiesterase 2 (TDP2) is implicated in 
topoisomerase-mediated repair of DNA damage. As a drug 
target, TDP2 is hypothesized to mediate drug resistance to 
topoisomerase II inhibition by etoposide [39]. Therefore, 
inhibition of TDP2 is proposed as a promising approach 
to overcome intrinsic or acquired resistance to topo II-
targeted drug therapy. The observed properties of screened 
small molecules to inhibit both targets could be exploited 
for the design of multitarget agents. Considering that the 
mechanisms of drug action for UCH37 and TDP2 differ 
significantly, the potential for drugs targeting both of them 
is likely to be more efficient than targeting independent 
mechanisms in the cancer cell. Therefore, multi-target 
drugs affecting several cancer mechanisms represented 
by UCH37 and TDP2 could be more efficient. On the 
other hand, TDP2 has been reported to be essential for 
normal neural function and is required to maintain normal 
levels of several gene transcripts in the mouse brain 
during development [40]. Therefore, targeting TDP2 has 
increased odds to be associated with neurological side 
effects. 
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suMo-lation assays
Targeting SUMOylation has become an important 
drug discovery trend considering the number of HTS 
assays developed (see table 1). Targeting SUMOylation 
has been considered as a drug discovery strategy to 
overcome cancer cell resistance to chemo and radiation 
therapy [41]. In particular, some studies specifically 
search for small molecule inhibitors of protein-protein 
interactions mediated by SUMO. The rationale in 
developing an HTS assay “identification of SUMO1-
mediated protein-protein interactions” was a demand for 
discovery of small molecules that can specifically act as 
“chemical modulators” of SUMO-mediated signaling. 
The assay was developed on the principal of time-
resolved fluorescence resonance energy transfer (TR-
FRET) based on a N-terminal-fluorescein tagged-SUMO 
1 specific sequence peptide. The binding event brings the 
fluorescein acceptor moiety in close proximity to the Tb-
donor to allow time-resolved lanthanide fluorescence from 
the terbium. In total, a library of 362962 small molecules 
was screened and 1206 molecules were reported as active 
(efficiently inhibiting SUMO1-mediated protein-protein 
interactions (PPI) at low concentrations).
The top ten potential off target activities for the 
small molecule inhibitors of PPI mediated by SUMO 
are presented in Table 4. For example, the ability of a 
molecule to inhibit MBD2 significantly increases odds (~ 
110 fold) for the molecule to inhibit SUMO1-mediated 
PPI. In total, 258 (82 + 176) molecules tested in the assay 
have been reported in other HTS screens as efficient 
inhibitors of MBD2 and 82 of them demonstrated potent 
inhibition of SUMO1-mediated PPI. Observed odds for a 
molecule to inhibit SUMO1-mediated PPI in the screen 
is ~ 0.0045 (1091/241605), while observed odds for the 
molecules known to inhibit MBD2 is approximately 100 
times higher ~ 0.45 (82/176). Thus, we observe a strong 
association between MBD2 and SUMO1-mediated PPI: 
again, molecules targeting one have a reasonable chance 
to target the other one as an off target. 
Among the top potential off targets for the molecules 
inhibiting SUMO1-mediated PPI we can see proteins 
commonly associated as drug targets against cancer. 
For example, MBD2 belongs to the family of methyl-
CpG binding proteins [42]. MBD2 mediates epigenetic 
gene silencing and thus is an attractive target in cancer 
treatment for reactivation of apoptotic genes as a primary 
therapeutic mechanism. Another off target WRN is RecQ 
DNA helicase that participates in suppression of DNA 
hyper-recombination and repair. WRN was considered as 
a cancer therapeutic target in hypopharyngeal carcinomas, 
which have the worst prognosis among head and neck 
squamous cell carcinomas (HNSCC) with a rapidly 
rising incidence [43]. It has been shown that WRN is 
highly expressed in HNSCC, and that siRNA-mediated 
silencing of the gene suppressed carcinoma cell growth 
in vitro. Therefore, there are several potential off targets 
for the molecules inhibiting SUMO1-mediated PPI which 
are potential anticancer targets. As has been already 
mentioned, this knowledge could be utilized for the 
development of multitarget drugs and which may therefore 
provide therapeutic intervention affecting multiple 
independent anticancer mechanisms.
On the other hand, there are two potential off targets 
which seem better avoided. The HKDC1 (HexoKinase 
table 3: top off targets for molecules inhibiting ucH37 (based on data from assay “A screen for small 
molecule inhibitors of the human deubiquitinating enzyme, ucH37”). 
(target): activity odds ratio kA* 
KA 
(the 
number 
of Active 
molecules)
kB**
KB *** 
(the number 
of InActive 
molecules)
P-value
(USP1):inhibitor 69.85 158 1074 508 206210 4.73E-211
(PAFAH1B3):inhibitor 55.05 140 1074 560 206210 3.35E-175
(TDP2):inhibitor 30.25 119 1074 846 206210 3.14E-122
(HKDC1):inhibitor 30.11 55 1074 369 206210 5.08E-58
(APAF1):inhibitor 24.98 181 1074 1660 206210 4.65E-169
(WHSC1):inhibitor 21.86 124 1074 1224 206210 2.06E-111
(CASP6):inhibitor 20.33 115 1074 1209 206210 2.07E-100
[RBBP9]:inhibitor 19.4 61 1074 638 206210 1.27E-53
(CTSL1):inhibitor 18.09 98 1074 1138 206210 1.07E-81
[FadD28]:competitors for binfing 17.23 52 1074 607 206210 1.20E-43
*     kA – the number of Active molecules known to have off target activity
**   kB – the number of InActive molecules known to have off target activity
*** Molecules that have no experimentally validated targets are not accounted in the table
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Domain Containing I) gene encodes mammalian 
hexokinase. Hexokinases (HKs) catalyse the first step in 
glucose metabolism and play a major role in regulating 
the metabolic fate of glucose in the tissues where they 
are expressed. The dysregulation of glucose is commonly 
associated with Type 2 diabetes, and activation of 
HKDC1 is considered as a potential target for diabetes 
therapeutics while inhibition of HKDC1 could lead to 
the undesired inhibition of glucose metabolism [44]. Rap 
guanine nucleotide exchange factor (the gene is known as 
RAPGEF3, but the protein is usually referred to as EPAC) 
is closely involved in the regulation of cAMP signaling. 
EPAC has been implicated in playing important roles in 
major human pathological conditions such as diabetes 
and heart disease and EPAC is now considered as a new 
regulator of cardiac physiopathology [45]. Although 
its effects are much less well known than the classical 
cAMP effector, PKA, several studies have investigated 
the cardiac role of EPAC, providing evidence that EPAC 
modulates intracellular Ca(2+) levels. In one of the 
first analyses, it was shown that EPAC can increase the 
frequency of spontaneous Ca(2+) oscillations in cultured 
rat cardiomyocytes. Considering that drugs targeting 
EPAC have increased chances to lead to unexpected 
cardiac side effects, it would be better to select drug leads 
with SUMO1-mediated PPI activities that do not possess 
activity towards RAPGEF3 gene products to minimize 
these risks.
sEnP assays
A group of proteases known as SENPs are 
involved in both the maturation of SUMO precursors 
(endopeptidase cleavage) and deconjugation of the targets 
(isopeptidase cleavage) [46]. Human cells contain seven 
SENPs (SENPs -1, -2, -3, -5, -6, -7, and -8), and several 
of these have been characterized as SUMO (or Nedd8) 
endopeptidases or isopeptidases [47]. The importance of 
SENPs as drug targets is emphasised by the evidence that 
SUMOlation regulates cell fate decisions by regulating 
p53, mdm2, and PML activity [41, 48]. A number of 
assays covering SENP1, SENP6, SENP7 and SENP8 have 
been developed recently (see table 1). The objective of the 
assays was to identify small molecule inhibitors specific 
for SENP6, SENP7 and SENP8. The assays utilized 
an RLRGG-aminoluciferin peptide substrate and used 
SENP8-dependent deconjugation of the aminoluciferin, 
which serves as a substrate for the coupled luciferase. In 
total, libraries covering ~ 300000 small molecules were 
screened versus the SENP family and several thousand 
molecules were reported as active (efficiently inhibiting 
SENP proteases at low concentration). Table 5 reports 
the top 10 ten potential off target activities for the small 
molecule inhibitors of SENP6. 
The ability of a molecule to inhibit SENP6 observed 
in the assay was very strongly correlated with the ability 
of the molecule to inhibit other SENP family members: 
SENP7 and SENP8. This could be partially explained 
by technical bias. The assays are based on Caspase-3 
dependent deconjugation of the aminoluciferin, which 
serves as a substrate for the coupled Ultra-GloTM 
luciferase. Therefore, molecules inhibiting CASP3 will 
also provide an artefactual signal in the assay. For this 
reason several control assays have been carried out in 
order to deprioritize compounds that inhibit Caspase-3. 
As it can be seen from table 5, the majority of molecules 
detected in the initial screen for potential SENP inhibitors 
are also Caspase-3 inhibitors. Considering the numbers, 
table 4: top off targets for molecules inhibiting suMo1-mediated PPI (based on data from assay “uHts 
identification of SUMO1-mediated protein-protein interactions”). 
(target): activity o d d s ratio kA* 
KA 
(the num-
ber of Ac-
tive mol-
ecules)
kB**
KB *** 
(the number 
of InActive 
molecules)
P-value
(MMP2):inhibitor 144.62 68 1091 111 241605 4.66E-111
(MBD2):inhibitor 111.48 82 1091 176 241605 4.35E-126
(ACP1):inhibitor 105.01 224 1091 593 241605 < 1.57E-280
(PTPN5):inhibitor 88.51 216 1091 672 241605 < 1.57E-280
(BLM):inhibitor 85.02 87 1091 246 241605 3.85E-125
(HKDC1):inhibitor 73.78 125 1091 423 241605 1.17E-171
(WRN):inhibitor 69.34 314 1091 1400 241605 < 1.57E-280
(DNMT1):inhibitor 69.02 459 1091 2516 241605 < 1.57E-280
(RAPGEF3):antagonist 66.59 108 1091 398 241605 9.99E-145
*     kA – the number of Active molecules known to have off target activity
**   kB – the number of InActive molecules known to have off target activity
*** Molecules that have no experimentally validated targets are not accounted in the table
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we can see that more than 80 percent of active molecules 
are non-specific in relation to either CASP3 or other 
family members.
As in previous cases, there a number of off target 
activities which can be utilized for development of 
multitarget drugs as well as some specific off targets 
which are better to be avoided. For example, the molecules 
inhibiting the SENP family seem to have increased odds 
(~23 fold) to reactivate p53. Lack of p53 expression or 
expression of mutant p53 is common in human cancers 
and is associated with increased tumor growth and 
resistance to therapies [49, 50]. Significant efforts toward 
pharmaceutical reactivation of defective p53 by small 
molecules are considered as an independent anticancer 
therapeutic strategy [51-54]. Indeed, reactivated p53 
can lead to tumor destruction [55]. Therefore, selecting 
drug candidates for the next developmental stages from 
SENPs screens where reactivation of p53 is a potential off 
target activity would increase the chances of developing 
potent anticancer agents that target independent anticancer 
mechanisms.
On the other hand, those molecules inhibiting the 
SENP family seem to have increased odds (~140 fold) to 
inhibit PKM (pyruvate kinase, muscle). Pyruvate kinase 
is a key glycolytic enzyme which is expressed as several 
isoforms in many cell types (liver, pancreatic cells, small 
intestine and so on). PKM has been reported to have 
important roles in many diseases including cancer and 
PKM polymorphisms have been shown to be associated 
with type 2 diabetes [56]. Considering the complicated 
and controversial role of PKM in human diseases, it would 
be better to avoid potential drug leads that additionally 
target PKM. 
dIscussIon
There have been significant efforts in recent 
years to discover small molecular potent inhibitors 
of ubiquitin–proteasome or ubiquitin-like signalling 
systems including a number of high-throughput screening 
projects which reported thousands of potential drug lead 
molecules efficiently targeting disease specific UPS-UBL 
components in vitro [18, 20-22]. A critical step in drug 
discovery is a selection of those drug leads that have 
better chances of success in clinical trials [57]. Selected 
molecules are subjected to a number of preclinical tests 
to address potential issues with pharmacodynamics, 
pharmacokinetics, ADME properties and potential 
toxicity. Considering the low rate of success in current 
drug discovery, any rationale for improving the selection 
process of drug leads that increases the chances of 
avoiding further safety [58] or efficacy issues [59-61] is 
of paramount importance. 
It is now commonly accepted that polypharmacology 
(the ability to affect multiple independent protein 
targets) is a basic property of small molecules [60, 62-
64]. Therefore, understanding the potential off target 
spectrum of molecules targeting UPS(UBL) is of 
practical importance [65, 66]. Here we have explored the 
abundance of publicly available high-throughput screening 
assay data in order to understand polypharmacology of 
small molecules tested in UPS-UBL high-throughput 
table 5: top off targets for molecules inhibiting sEnP6 (based on data from assay “uHts Luminescent 
assay for identification of inhibitors of Sentrin-specific protease 6 (SENP6)”).
(target): activity odds ratio kA* 
KA 
(the 
number 
of Active 
molecules)
kB**
KB *** 
(the number 
of InActive 
molecules)
P-value
(SENP7):inhibitor 1156.49 4904 5779 1059 219581 < 1.57E-280
(CASP3):inhibitor 1111.03 3950 5779 426 219581 < 1.57E-280
(SENP8):inhibitor 459.86 4734 5779 2142 219581 < 1.57E-280
(PKM):inhibitor 138.06 107 5779 30 219581 1.57E-141
(MMP14):inhibitor  transcription 30.53 225 5779 291 219581 1.07E-211
(TNFRSF10B):inhibitor 27.9 1148 5779 1934 219581 < 1.57E-280
(NPC1):activator 27.67 2286 5779 5074 219581 < 1.57E-280
(RAB9A):activator 26.6 2550 5779 6331 219581 < 1.57E-280
(STAT3):inhibitor 23.94 572 5779 1003 219581 < 1.57E-280
(TP53):re-activators of p53 using a 
Luc reporter 23.47 105 5779 173 219581 2.25E-91
*     kA – the number of Active molecules known to have off target activity
**   kB – the number of InActive molecules known to have off target activity
*** Molecules that have no experimentally validated targets are not accounted in the table
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screens (Table 1). To do this, we interrogated (> 1000) 
HTS target oriented screens available in the public domain 
(PubChem repository [25]), which cover a wide spectrum 
of commonly accepted drug targets for various diseases. 
The opportunity of such statistical analysis stems from the 
fact that the chemical libraries used in most of these high-
throughput screens share a significant number of common 
molecules. Thus we computed for each UPS(UBL) 
target the off target spectrum by counting the number 
of molecules which are reported to be active/inactive 
between a pair of assays (UPS-UBL assay versus off target 
assay) and thus computed the shift in odds for a molecule 
to target a specific component of the UPS while being 
experimentally validated to target another given protein. 
For each UPS(UBL) target we derived the list of top off 
targets (off target spectrum) which have high odds to be 
targeted by potential UPS(UBL) drug leads. 
Polypharmacology of a small molecule could be 
either beneficial (co-targeting of certain proteins could 
increase efficiency) or the opposite (co-targeting of 
certain proteins could lead to undesired side effects). Here 
we have demonstrated that information for potential off 
targets for molecules targeting different UPS components 
could be utilized to design multi-target drugs, which are 
able to affect independent disease specific mechanisms. 
For example, from the HTS data we observed a strong 
correlation between drugs targeting Ubc13 and APAF1. 
Both targets could be potentially implicated in treatment 
of the pathogenic aggregation of mutant proteins in 
neurodegenerative diseases such as Huntingtons disease, 
although targeting different mechanisms. This observation 
(pharmacological association between Ubc13 and APAF1) 
can be utilized in future efforts to identify potent drug 
leads that inhibit both targets and, therefore, by affecting 
two independent mechanisms in neurodegenerative 
diseases the potential efficacy of the multitarget therapy 
is enhanced. 
Finally, we have demonstrated that information 
for potential off targets for molecules targeting different 
UPS components could be utilized to reduce risks 
associated with potential side effects of drug leads. Among 
pharmacologically associated off targets for different UPS 
targets there are multiple proteins known to be associated 
with various disease conditions such as cardiovascular or 
diabetes. For design of anticancer agents, for example, 
these types of off targets should be avoided as inhibition 
or activation of these proteins might have undesirable 
corresponding side effects.
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